ESTRO 2025 - Abstract Book

S632

Clinical - Breast

ESTRO 2025

financial support from friends and relatives (N=28, 25,4%), less than one-fifth from the authorities, but some of them did not search for support, despite needing it (N=7; 6.4%).

Conclusion: Breast cancer patients face various financial challenges after diagnosis, having significant out-of-pocket expenses compared to their income.

Keywords: breast cancer, financial toxicity, healthcare

4556

Digital Poster Capecitabine-Radiotherapy Combination in Triple-Negative Breast Cancer: Impact on Skin Toxicities

sirine zouari, daghfous yasmine, Dhouib fatma, wafa mnejja, daoud jamel Habib bourguiba university hospital, radiation oncology, sfax, Tunisia

Purpose/Objective: The addition of capecitabine in the adjuvant setting improves overall survival in patients with breast cancer who have not achieved a pathological complete response after neoadjuvant chemotherapy. However, concerns remain regarding the exacerbation of radiodermatitis in patients receiving capecitabine in combination with radiotherapy (RT). This study aimed to assess the risk of increased skin toxicities with this therapeutic combination Material/Methods: This is a retrospective study that included patients with triple-negative breast cancer treated between 2021 and 2023. We reviewed the medical records of patients with residual disease after neoadjuvant chemotherapy who were treated with adjuvant chemoradiotherapy including capecitabine. Radiotherapy was delivered using a hypofractionated regimen, and capecitabine was administered at a dose of 825 mg/m² twice daily. Skin toxicity was evaluated using the Common Terminology Criteria for Adverse Events, version 5.0. Results: Twelve patients were included in this study. Only two patients (16%) had breast-conserving surgery. The tumor size was less than 2 cm in six patients (50%). Eleven patients (92%) completed the adjuvant chemotherapy without interruption or dose reduction. Grade 1 radiodermatitis was reported in the majority of patients (66%, or eight patients). Only one patient (8.3%) developed grade 2 radiodermatitis Conclusion: Adjuvant chemoradiotherapy with capecitabine is feasible and well tolerated in patients with triple-negative breast cancer. Due to the radiosensitizing properties of capecitabine, this approach may offer additional survival benefits for these patients while being associated with relatively moderate skin toxicity.

Keywords: Capecitabine, Radiotherapy, Skin Toxicities